Vanda Pharmaceuticals (VNDA) Key Ratios

$5.34

up-down-arrow $-0.19 (-3.44%)

As on 03-Sep-2026 16:00EDT

Market cap

info icon

$320 Mln

Revenue (TTM)

info icon

$216 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

1.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -2.30 -3.92 6.02 -3.27 -3.56
EBIT -34.71 -86.99 -125.84 -298.00 -234.04
Net Profit -28.71 -129.77 -310.61 -364.21 -253.32
EPS -27.08 -125.07 -305.65 -360.94 -251.73
Book Value -- -- -40.06 -15.63 -7.15
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -27.64-12.54-83.46-64.16-11.53
Net Margin info -----127.41----
Return on equity info -17.98-9.16-100.43-50.93-3.49
Return on Capital info -17.49-8.91---49.51-3.42
Return on Assets info -13.67-6.82-41.56-38.51-2.90
Debt to Equity (x) info ----0.000.040.02
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
-49.51
-3.42
0.46
1.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-100.43

Lower than Peers by 60.03

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
-100.43
-50.93
-3.49
0.47
1.22
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-41.56

Lower than Peers by 10.58

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
-41.56
-38.51
-2.90
0.39
1.02
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-83.46

Higher than Peers by 0.15

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
-83.46
-64.16
-11.53
-7.24
4.44
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-127.41

Lower than Peers by 34.74

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
-127.41
-102.02
-9.51
1.30
2.47
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Higher than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

6.02

Lower than Peers by 47.93

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
6.02
0.09
0.03
-0.24
-0.05
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-125.84

Lower than Peers by 125.04

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
-125.84
-504.89
-64.28
-223.47
-73.33
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-310.61

Lower than Peers by 303.31

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
-310.61
-1,066.53
-853.29
-60.02
-81.07
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-305.65

Lower than Peers by 320.30

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
-305.65
-10.51
-8.43
-0.60
-0.81
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-55.65

Lower than Peers by 45.47

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
-55.65
--
--
--
--
Peer Median
-10.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
0.04
0.02
0.02
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.02

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
0.02
0.02
0.01
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.61

Lower than Peers by 4.20

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
1.61
2.39
4.39
4.94
5.68
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.60

Lower than Peers by 4.09

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
1.60
2.38
4.37
4.92
5.67
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
--
--
--
2.27
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

27.67

Higher than Peers by 8.53

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
27.67
25.26
23.70
17.73
13.17
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.33

Higher than Peers by 0.26

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
0.33
0.38
0.30
0.30
0.41
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
85.93
74.66
64.15
47.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
50.09
49.76
26.51
16.69
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
118.14
171.79
206.12
102.40
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
17.88
-47.37
-115.46
-38.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
-2.36
-14.78
96.77
67.35
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

1.49

Lower than Peers by 3.69

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
1.49
1.59
0.52
0.45
0.80
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

0.76

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
0.76
-2.13
5.61
9.75
-2.36
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

320

Higher than Peers by 174

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vanda Pharmaceuticals (VNDA)
320
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...